Cargando…
Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old
Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021. We sought to explore LAI-PrEP decision-making among a nationwide sample of young sexual minority men (YSMM) 17–24 years old. In 2020, HIV-negative/unknown YSMM (n...
Autores principales: | John, Steven A., Zapata, Juan P., Dang, Madeline, Pleuhs, Benedikt, O’Neil, Andrew, Hirshfield, Sabina, Walsh, Jennifer L., Petroll, Andrew E., Quinn, Katherine G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052280/ https://www.ncbi.nlm.nih.gov/pubmed/36991027 http://dx.doi.org/10.1038/s41598-023-32014-8 |
Ejemplares similares
-
Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.
por: Pleuhs, Benedikt, et al.
Publicado: (2022) -
PrEP Use and Persistence Among Young Sexual Minority Men 17–24 Years Old During the COVID-19 Pandemic
por: Hong, Chenglin, et al.
Publicado: (2021) -
Preferred Characteristics for mHealth Interventions Among Young Sexual Minoritized Men to Support HIV Testing and PrEP Decision-Making: Focus Group Study
por: Zapata, Juan Pablo, et al.
Publicado: (2023) -
Preferences for pre-exposure prophylaxis (PrEP) among sexual and gender minorities: a discrete choice experiment in Brazil
por: Pereira, Claudia Cristina de Aguiar, et al.
Publicado: (2023) -
Patterns of Pre-exposure Prophylaxis (PrEP) Use in a Population Accessing PrEP in Jackson, Mississippi
por: Chase, Erin, et al.
Publicado: (2022)